Targeting the CARHSP1/TNF-α inflammatory signaling activation induced by radiotherapy might directly affect radioresistance and presents an attractive therapeutic target for GBM, particularly for patients with high levels of CARHSP1. Here, CARHSP1 is linked to glioblastoma.